bimekizumab
ucb pharmaceuticals
['bimekizumab', 'psoriatic arthritis']
phase2b: sustained efficacy over 3 years of bimekizumab (il-17 a+f) in psoriatic arthritis. no new safety issues. #acr22 #acrambassador 
Tweeting anything #Rheum #COVID-19
MD | PhD | Rheumatology #RheumTwitter